Lupin launches ivabradine in India
This article was originally published in Scrip
Lupinhas received approval from the Drugs Controller General of India to launch Ivabrad (ivabradine) 5mg and 7.5mg tablets on the domestic market. Ivabrad is used for the treatment of symptomatic chronic stable angina in patients with coronary artery disease. Traditional heart rate–lowering agents reduce the myocardial contractility, which is harmful when ventricular function is already impaired. Ivabradine reduces heart rate but maintains myocardial contractility and atrioventricular conduction. The cardiac market in India is estimated at about Rs36 billion ($755.3 million) and is growing at 18%. Lupin's cardiovascular business reported sales of Rs1.75 billion in 2007-08 as compared with Rs1.30 billion in 2006-07 and the company has a market share of 5.03%.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.